NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Matchpoint Therapeutics

Matchpoint Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://matchpointtx.com/

Last Round

Corporate Funding

Jul 24, 2025

Total Funding Raised

$130M

Company Overview

Matchpoint Therapeutics is a biotechnology company that develops precision small molecule medicines leveraging covalency to treat immune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

precision medicinecovalent inhibitorsdrug discoverycovalent chemistrybiotechimmune diseasechemoproteomicsai drug discoveryoral inhibitorsinflammatory diseasepharma partnershipdrug discovery platformprotein targetingin silico drug designbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Matchpoint Therapeutics Comparables

Compare Matchpoint Therapeutics with similar companies based on industry and business-model similarity.

Matchpoint Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Totus Medicines
86%
Enlaza Therapeutics
79%
Dunad Therapeutics
77%

Matchpoint Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingJul 24, 2025
Series AOct 14, 2022
SeedNov 30, 2021
SeedNov 1, 2021

Key People

Founding team and executive leadership

Andre Turenne

President And CEO

Executive Team

Matchpoint Therapeutics Investors

Notable investors and investment history

Matchpoint Therapeutics investors
InvestorRounds
Access IndustriesSeed
Vertex Ventures HCSeries A
Digitalis VenturesSeries A
Alexandria Venture InvestmentsSeries A
Sanofi VenturesSeries A
Atlas VentureSeries A, Seed
Access BiotechnologySeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2025

    $60M raised in corporate funding.

  • Jul 24, 2025

    Exclusive option and license deal with Novartis for inflammatory disease inhibitors.

Matchpoint Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Matchpoint Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Matchpoint Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range32
Year Founded2021
Last FundingJul 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.